Co-management of the liver and the kidney： New prospects in the clinical management of metabolic dysfunction-associated fatty liver disease with chronic kidney disease
- VernacularTitle:“肝肾”共管： 代谢相关脂肪性肝病合并慢性肾病临床管理新曙光
- Author:
Qiongyue FAN
1
;
Danqin SUN
2
;
Chunsun DAI
3
;
Minghua ZHENG
1
Author Information
- Publication Type:Journal Article
- Keywords: Metabolic Dysfunction-associated Fatty Liver Disease; Kidney Diseases; Disease Management
- From: Journal of Clinical Hepatology 2025;41(9):1744-1751
- CountryChina
- Language:Chinese
- Abstract: This article investigates the collaborative management of metabolic dysfunction-associated fatty liver disease （MAFLD） and chronic kidney disease （CKD）. As major public health issues worldwide， MAFLD and CKD are closely related in terms of epidemiology， pathogenesis， and management strategies， and however， there are still many challenges in the multidisciplinary collaborative management of the two diseases. This article systematically elaborates on the epidemiology of MAFLD and CKD， summarizes their common risk factors such as metabolic disorder， genetic susceptibility， and active metabolites， and reviews the mutual screening strategies and combined management models based on noninvasive imaging， serum markers， FIB-4 score， and liver stiffness measurement. In addition， this article summarizes the advances in the application of lifestyle intervention and new drugs （such as GLP-1 receptor agonists and SGLT-2 inhibitors） and emphasizes the importance of multidisciplinary collaboration in improving the prognosis of patients. Due to the close association between MAFLD and CKD， their joint management is crucial， and therefore， it is necessary to establish a multidisciplinary collaboration mechanism and implement the measures of precise screening， comprehensive treatment， and long-term monitoring， so as to improve the prognosis of patients and reduce the risk of complications. Finally， this article proposes that in the future， more effective combined treatment regimens should be explored to expand the clinical options for the co-management of the liver and the kidney.
